We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Hvivo Plc (HVO) Ord 0.1p

Sell:27.80p Buy:28.10p 0 Change: No change
FTSE AIM 100:0.38%
Market closed |  Prices as at close on 3 May 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:27.80p
Buy:28.10p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 3 May 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:27.80p
Buy:28.10p
Change: No change
Market closed |  Prices as at close on 3 May 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Share news, reports & tips

  • Hvivo unveils record results and bullish growth targets

    9 April 2024 08:58

    (Sharecast News) - Shares in AIM-listed Hvivo dipped on Tuesday despite the infectious and respiratory disease treatment firm reporting a record year across all financial and operational metrics, as well as...

  • hVIVO secures £6.3m contract with biotech client

    2 January 2024 08:56

    (Sharecast News) - Infectious and respiratory disease study group hVIVO has inked a £6.3m contract with an unnamed biotechnology client to test an antiviral candidate using its common cold virus human...

  • Sunday share tips: hVivo and On the Beach

    24 December 2023 11:06

    (Sharecast News) - Drug-testing specialist hVivo was one of the top tips for 2023 from The Daily Mail's Midas column, but the paper still reckons there's further to go despite the stock doubling in...

  • HVivo jumps on contract win, guidance upgrade

    13 December 2023 08:20

    (Sharecast News) - Shares in AIM-listed HVivo jumped on Wednesday morning after the clinical trials and laboratory services group won a new £17m contract and announced it was trading ahead of guidance.

  • hVIVO upbeat on positive results from recent FluCamp study

    5 October 2023 15:15

    (Sharecast News) - Contract research organisation hVIVO announced on Thursday that in a recent phase 2a influenza human challenge study it conducted, Pneumagen's antiviral candidate Neumifil...

  • hVIVO announces new Canary Wharf trial facility

    29 August 2023 14:17

    (Sharecast News) - Human challenge trial specialist hVIVO announced plans to open a new state-of-the-art facility at the rapidly-expanding life sciences hub in Canary Wharf, London on Tuesday.

  • hVIVO manufactures human challenge agent for Omicron

    16 March 2023 15:48

    (Sharecast News) - Specialist contract research organisation hVIVO has successfully manufactured its Omicron human challenge agent, it announced on Thursday.

  • hVIVO inks £5.2m contract with biotechnology group

    4 January 2023 07:50

    (Sharecast News) - Contract research organisation hVIVO has signed a £5.2m contract with a global biotechnology company to test its respiratory syncytial virus vaccine candidate.

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2024. All rights reserved.

Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.